arrow
J

Joe Yeong

Duke-NUS Medical School
H指数:37
被引数:6,552

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Nur77 agonism invigorates Natural Killer cell immunity against hepatocellular carcinoma

Nur77激动剂增强针对肝细胞癌的自然杀伤细胞免疫

2026-06-300
OAAI
Spatial predictors of response to chemo-immunotherapy in microsatellite stable metastatic colorectal cancer

微卫星稳定型转移性结直肠癌对化疗免疫联合治疗的反应的空间预测因子

2026-04-250
OAAI
Tumor immune microenvironment delineates progression trajectories of distinct nasopharyngeal carcinoma phenotypes

肿瘤免疫微环境描绘了不同鼻咽癌表型的进展轨迹

2025-05-230
OA
Tumor-immune partitioning and clustering algorithm for identifying tumor-immune cell spatial interaction signatures within the tumor microenvironment

肿瘤-免疫分区与聚类算法:用于识别肿瘤微环境内肿瘤-免疫细胞空间相互作用特征

2025-02-180
OA
Claudin-1 (CLDN1) expression in nasopharyngeal carcinoma (NPC): Association with immune exclusion and implications for immune checkpoint inhibitor (ICI) therapy

Claudin-1 (CLDN1)在鼻咽癌(NPC)中的表达:与免疫排斥的关系及其对免疫检查点抑制剂(ICI)治疗的启示

2024-12-010
PRE
Aristolochic acid-related renal cell carcinoma exhibits a distinct tumor-immune microenvironment favoring response to immune checkpoint blockade

马兜铃酸相关肾细胞癌表现出独特的肿瘤免疫微环境,有利于对免疫检查点阻断的反应

2024-10-030
OA
Claudin-1 (CLDN1) tight junction protein expression delineates distinct immune infiltrates in ascending (A) vs descending (D) subtypes of nasopharyngeal carcinoma: Potential implications for treatment selection

Claudin-1 (CLDN1)紧密连接蛋白的表达可区分鼻咽癌升型(A)与降型(D)亚型中不同的免疫浸润:对治疗选择可能存在潜在影响

2024-09-010
PRE
Differences in antigen and immune marker expression in lymphoepithelioma-like carcinoma (LELC) and nasopharyngeal carcinoma (NPC): A multiplex immunohistochemistry (mIHC), spatial transcriptomic and multiplex immunofluorescence (mIF)-based analysis

抗原和免疫标志物表达在淋巴上皮样癌(LELC)和鼻咽癌(NPC)中的差异:基于多色免疫组化(mIHC)、空间转录组学和多重免疫荧光(mIF)的分析

2024-09-010
PRE
A phase I dose escalation study of EBC-129, a first-in class, anti N-glycosylated CEACAM5 & CEACAM6 antibody-drug conjugate (ADC) in patients with solid tumors

一项关于EBC-129的I期剂量递增研究,EBC-129是一种首创的、抗N-糖基化CEACAM5与CEACAM6抗体药物偶联物(ADC),用于实体瘤患者。

2024-09-010
PRE
Comprehensive molecular characterization of collecting duct carcinoma for therapeutic vulnerability

集合管癌治疗易损性的综合分子表征

2024-08-090
PRE
Integrative Multi-Omics Enhancer Activity Profiling Identifies Therapeutic Vulnerabilities in Cholangiocarcinoma of Different Etiologies
2024-04-150
PRE